JP2018523711A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018523711A5 JP2018523711A5 JP2018528106A JP2018528106A JP2018523711A5 JP 2018523711 A5 JP2018523711 A5 JP 2018523711A5 JP 2018528106 A JP2018528106 A JP 2018528106A JP 2018528106 A JP2018528106 A JP 2018528106A JP 2018523711 A5 JP2018523711 A5 JP 2018523711A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- ion
- composition according
- diabetes
- clo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 206010012601 diabetes mellitus Diseases 0.000 claims description 11
- XTEGARKTQYYJKE-UHFFFAOYSA-M Chlorate Chemical compound [O-]Cl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-M 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 6
- 229910001415 sodium ion Inorganic materials 0.000 claims description 6
- 208000008960 Diabetic foot Diseases 0.000 claims description 5
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 claims description 3
- 229940005989 chlorate ion Drugs 0.000 claims description 3
- QBWCMBCROVPCKQ-UHFFFAOYSA-M chlorite Chemical compound [O-]Cl=O QBWCMBCROVPCKQ-UHFFFAOYSA-M 0.000 claims description 3
- 229940005993 chlorite ion Drugs 0.000 claims description 3
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 206010038923 Retinopathy Diseases 0.000 claims description 2
- 206010039020 Rhabdomyolysis Diseases 0.000 claims description 2
- 208000002903 Thalassemia Diseases 0.000 claims description 2
- 208000029078 coronary artery disease Diseases 0.000 claims description 2
- 208000007475 hemolytic anemia Diseases 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000001747 exhibiting effect Effects 0.000 claims 2
- 206010062237 Renal impairment Diseases 0.000 claims 1
- 230000005977 kidney dysfunction Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- -1 chlorite ions Chemical class 0.000 description 6
- 229910001919 chlorite Inorganic materials 0.000 description 3
- 229910052619 chlorite group Inorganic materials 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021078253A JP2021130664A (ja) | 2015-08-20 | 2021-05-06 | 赤血球疾患およびそれによって媒介される症状を治療するための亜塩素酸塩の使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562207774P | 2015-08-20 | 2015-08-20 | |
| US62/207,774 | 2015-08-20 | ||
| PCT/IB2016/055011 WO2017029648A1 (en) | 2015-08-20 | 2016-08-22 | Use of chlorite to treat red blood cell diseases and indications mediated thereby |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078253A Division JP2021130664A (ja) | 2015-08-20 | 2021-05-06 | 赤血球疾患およびそれによって媒介される症状を治療するための亜塩素酸塩の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018523711A JP2018523711A (ja) | 2018-08-23 |
| JP2018523711A5 true JP2018523711A5 (enExample) | 2019-10-03 |
| JP6900596B2 JP6900596B2 (ja) | 2021-07-07 |
Family
ID=56896735
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018528106A Active JP6900596B2 (ja) | 2015-08-20 | 2016-08-22 | 赤血球疾患およびそれによって媒介される症状を治療するための亜塩素酸塩の使用 |
| JP2021078253A Pending JP2021130664A (ja) | 2015-08-20 | 2021-05-06 | 赤血球疾患およびそれによって媒介される症状を治療するための亜塩素酸塩の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078253A Pending JP2021130664A (ja) | 2015-08-20 | 2021-05-06 | 赤血球疾患およびそれによって媒介される症状を治療するための亜塩素酸塩の使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11813234B2 (enExample) |
| EP (1) | EP3337489B1 (enExample) |
| JP (2) | JP6900596B2 (enExample) |
| CN (1) | CN108135930A (enExample) |
| RU (1) | RU2018109574A (enExample) |
| WO (1) | WO2017029648A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112168841A (zh) * | 2019-07-05 | 2021-01-05 | 卢序 | 一种增加人一氧化氮生物利用度的方法 |
| CN112386606A (zh) * | 2019-08-19 | 2021-02-23 | 卢序 | 一种有第二信使作用增加积极氧化压力的氧化剂的用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU754928B2 (en) | 1997-10-06 | 2002-11-28 | Oxo Chemie Ag | Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response |
| US20040224306A1 (en) | 1999-11-30 | 2004-11-11 | Frederich-Wilhelm Kuhne | Evaluating and predicting clinical outcomes by gene expression analysis |
| EP1558237A4 (en) * | 2002-09-27 | 2007-01-17 | Martek Biosciences Corp | IMPROVED BLOOD SUGAR CONTROL F RPRU-DIABETES AND / OR DIABETES TYPE II USING DOCOSAHEXAENSURE |
| EP2081021A4 (en) * | 2006-10-16 | 2014-07-23 | Sekisui Chemical Co Ltd | HEMOGLOBIN DETERMINATION PROCESS |
| WO2008145376A1 (en) | 2007-06-01 | 2008-12-04 | Dimethaid Ag | Use of wf10 for treating allergic asthma, allergic rhinitis and atopic dermatitis |
| US20140287064A1 (en) * | 2009-04-28 | 2014-09-25 | Karen G. Swenholt | Compositions for improving the appearance and/or treating fungal infections of nails, mucus membranes and the integument |
| EA201290041A1 (ru) | 2009-08-06 | 2012-07-30 | Ньюралтус Фармасьютикалс, Инк. | Лечение расстройств, связанных с макрофагами |
| US20110118180A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to metformin |
| RU2014130080A (ru) | 2011-12-22 | 2016-02-10 | Нуво Рисерч Гмбх | Липосомальные композиции хлоритов или хлоратов |
| CN104519890A (zh) * | 2012-01-19 | 2015-04-15 | Ibt美国公司 | 四氯十氧(tcdo)的治疗应用 |
| US8748744B2 (en) * | 2012-06-28 | 2014-06-10 | Hubbell Incorporated | Electrical box extender assembly |
| CA2945179A1 (en) * | 2014-05-16 | 2015-11-19 | Michael S. Mcgrath | Methods and compositions for treatment of macrophage-related disorders |
-
2016
- 2016-08-22 US US15/753,516 patent/US11813234B2/en active Active
- 2016-08-22 EP EP16763581.2A patent/EP3337489B1/en active Active
- 2016-08-22 JP JP2018528106A patent/JP6900596B2/ja active Active
- 2016-08-22 CN CN201680061116.3A patent/CN108135930A/zh active Pending
- 2016-08-22 RU RU2018109574A patent/RU2018109574A/ru not_active Application Discontinuation
- 2016-08-22 WO PCT/IB2016/055011 patent/WO2017029648A1/en not_active Ceased
-
2021
- 2021-05-06 JP JP2021078253A patent/JP2021130664A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Flythe et al. | Dialysis for chronic kidney failure: a review | |
| Eyler et al. | Antibiotic dosing in critically ill patients with acute kidney injury | |
| Pea et al. | Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy | |
| JP2022009125A5 (enExample) | ||
| Jamal et al. | Improving antibiotic dosing in special situations in the ICU: burns, renal replacement therapy and extracorporeal membrane oxygenation | |
| Li et al. | A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy: do current studies supply sufficient data? | |
| Magder et al. | Fluids after cardiac surgery: a pilot study of the use of colloids versus crystalloids | |
| Woodward et al. | High dose insulin therapy, an evidence based approach to beta blocker/calcium channel blocker toxicity | |
| RU2018120182A (ru) | Плазминоген-заместительная терапия при дефиците плазминогена | |
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| JP2018172440A5 (enExample) | ||
| Remy et al. | Repurposing alpelisib, an anti‐cancer drug, for the treatment of severe TIE2‐mutated venous malformations: preliminary pharmacokinetics and pharmacodynamic data | |
| JP2017014206A5 (enExample) | ||
| Jang et al. | Drug dosing considerations in continuous renal replacement therapy | |
| Swift et al. | SCD-101: a new anti-sickling drug reduces pain and fatigue and improves red blood cell shape in peripheral blood of patients with sickle cell disease | |
| MX2015004296A (es) | Farmaco combinado que comprende gemigliptina y metformina, y metodo para su preparacion. | |
| Lee et al. | Hemodynamic changes in patients with influenza A after propacetamol infusion in the emergency department | |
| Ruiz et al. | Sublingual microcirculatory changes during high-volume hemofiltration in hyperdynamic septic shock patients | |
| Dell'Aglio et al. | Metformin overdose with a resultant serum pH of 6.59: survival without sequalae | |
| RU2018109574A (ru) | Применение хлорита для лечения болезней красных кровяных телец и опосредованных ими симптомов | |
| Mauro et al. | Clearance of linezolid via continuous venovenous hemodiafiltration | |
| Saini et al. | BRASH syndrome, the vicious cycle: A case report | |
| JP2023518829A5 (enExample) | ||
| Shashikala et al. | Refractory shock following ingestion of topical minoxidil solution | |
| EA201590825A1 (ru) | Способы контролирования кровяного давления и снижения диспноэ при сердечной недостаточности |